Skip to main content
. 2018 Apr 27;68(2):207–217. doi: 10.1136/gutjnl-2017-314549

Figure 3.

Figure 3

Human gastric cancer organoids show divergent therapy response to conventional chemotherapeutics. (A–E) Cell viability assay after treatment with 5-fluoruracil (5-FU), oxaliplatin, irinotecan, epirubicin and docetaxel in varying concentrations. Analysis for oxaliplatin, irinotecan, epirubicin and docetaxel treat was performed after 24 hours. Organoids treated with 5-FU were analysed 72 hours post-treatment. Values were normalised to untreated control organoids of the same patient. (F) Apoptosis assay using annexin V/propidium iodide (PI) flow cytometry (one example of three independent experiments is shown).